Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis

Handle URI:
http://hdl.handle.net/10754/621955
Title:
Cancer megafunds with <i>in silico</i> and <i>in vitro</i> validation: Accelerating cancer drug discovery <i>via</i> financial engineering without financial crisis
Authors:
Yang, Xianjin; Debonneuil, Edouard; Zhavoronkov, Alex; Mishra, Bud
Abstract:
Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.
KAUST Department:
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division; Applied Mathematics and Computational Science Program
Citation:
Yang X, Debonneuil E, Zhavoronkov A, Mishra B (2016) Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis. Oncotarget. Available: http://dx.doi.org/10.18632/oncotarget.9808.
Publisher:
Impact Journals, LLC
Journal:
Oncotarget
Issue Date:
3-Jun-2016
DOI:
10.18632/oncotarget.9808
Type:
Article
ISSN:
1949-2553
Sponsors:
B.M. is supported by an NCI PSOC grant# U54 CA193313.
Additional Links:
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=9808
Appears in Collections:
Articles; Applied Mathematics and Computational Science Program; Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division

Full metadata record

DC FieldValue Language
dc.contributor.authorYang, Xianjinen
dc.contributor.authorDebonneuil, Edouarden
dc.contributor.authorZhavoronkov, Alexen
dc.contributor.authorMishra, Buden
dc.date.accessioned2016-12-06T13:39:54Z-
dc.date.available2016-12-06T13:39:54Z-
dc.date.issued2016-06-03en
dc.identifier.citationYang X, Debonneuil E, Zhavoronkov A, Mishra B (2016) Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis. Oncotarget. Available: http://dx.doi.org/10.18632/oncotarget.9808.en
dc.identifier.issn1949-2553en
dc.identifier.doi10.18632/oncotarget.9808en
dc.identifier.urihttp://hdl.handle.net/10754/621955-
dc.description.abstractAdvances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.en
dc.description.sponsorshipB.M. is supported by an NCI PSOC grant# U54 CA193313.en
dc.publisherImpact Journals, LLCen
dc.relation.urlhttp://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=9808en
dc.rightsAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.en
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en
dc.subjectCancer megafunden
dc.subjectIn silico validationen
dc.subjectMegafunden
dc.subjectRBOen
dc.subjectResearch-backed obligationen
dc.titleCancer megafunds with <i>in silico</i> and <i>in vitro</i> validation: Accelerating cancer drug discovery <i>via</i> financial engineering without financial crisisen
dc.typeArticleen
dc.contributor.departmentComputer, Electrical and Mathematical Sciences and Engineering (CEMSE) Divisionen
dc.contributor.departmentApplied Mathematics and Computational Science Programen
dc.identifier.journalOncotargeten
dc.eprint.versionPublisher's Version/PDFen
dc.contributor.institutionUniversite Lyon 1, Laboratoire SAF, Franceen
dc.contributor.institutionInsilico Medicine, ETC, Johns Hopkins University, Baltimore, MD, United Statesen
dc.contributor.institutionCourant Institute, Tandon School of Engineering, NYUNY, United Statesen
kaust.authorYang, Xianjinen
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.